Moderna is a step closer to showing detractors that it is no moonshot stock. The biotech group on Monday said its experimental Covid-19 vaccine was 94.5 per cent effective, according to preliminary data. That makes it the second US company, after Pfizer and its German partner BioNTech, to report positive results from late-stage clinical trials.
Moderna朝著向詆譭者表明它不是成功幾率極小的股票走近了一步。這家生物技術集團週一表示，根據初步數據，其實驗性新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）疫苗的有效率達到94.5%。這使其成爲繼輝瑞(Pfizer)及其德國合作伙伴BioNTech之後、第二家報告後期臨牀試驗積極結果的美國公司。
您已閱讀17%（502字），剩餘83%（2397字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。